echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The first new new anti-flu drug in 20 years! Roche Xofluza declares listing in China

    The first new new anti-flu drug in 20 years! Roche Xofluza declares listing in China

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    On June 10th Roche's application for the listing of the flu drug Mabalosawe tablets in China was accepted by CDEXofluza is an oral antiviral drug called First-in-Class, which can be used once to treat oseltamivir-resistant strains of the virus and avian influenza virusUnlike the anti-flu drug that targets neuraminidase, Xofluza inhibits viral replication by inhibiting the influenza virus's cap-dependent nucleic acid endoenzyme, which acts as a drug in the early stages of influenza self-reproduction, so it blocks the flu faster than the neuraminase inhibitorDeveloped by Yano Yi/Roche, Xofluza was first approved in Japan in February 2018 and approved in the United States in October of the same year for the treatment of patients aged 12 and over with acute non-complications, making it the world's first new mechanism anti-influenza drug approved in nearly 20 years, and is now approved in Hong Kong, China and TaiwanIn October 2019, the FDA approved Xofluza's new indications for the treatment of people at high risk of flu complications 12 years and olderIn 2020Q1, Xofluza sales were CHF 28 million, an increase of 371% year-on-yearRoche has also submitted to the FDA applications for mabarosavir oral suspension for the treatment of acute influenza attacks in children ages 1 to 12 and for the use of tablets for post-flu prevention, both of which are expected to be approved in 2020/11/23Influenza causes about 3-5 million cases of severe illness worldwide each year, millions of patients are hospitalized and 650,000 die, creating a huge threat to public healthThe main flu treatment in the domestic market is The East Sun's cocourse (oseltamivir), which has sales of 5.94 billion yuan in 2019At present, the domestic has a number of oseltamivir generic drugs declared on the market, after approval will bring a certain impact to the East SunshineThe domestic flu market is expected to intensify after Roche's new anti-flu drug Xofluza is approved for sale.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.